Trade Bioventus Inc. - BVS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Bioventus Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 4.25 |
| Open* | 4.23 |
| 1-Year Change* | 350% |
| Day's Range* | 4.23 - 4.36 |
| 52 wk Range | 0.80-5.54 |
| Average Volume (10 days) | 178.97K |
| Average Volume (3 months) | 3.45M |
| Market Cap | 376.44M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 78.75M |
| Revenue | 502.76M |
| EPS | -1.97 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 29, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 4.25 | -0.19 | -4.28% | 4.44 | 4.47 | 4.24 |
| Apr 19, 2024 | 4.47 | -0.08 | -1.76% | 4.55 | 4.56 | 4.43 |
| Apr 18, 2024 | 4.54 | -0.15 | -3.20% | 4.69 | 4.69 | 4.47 |
| Apr 17, 2024 | 4.69 | 0.17 | 3.76% | 4.52 | 4.83 | 4.52 |
| Apr 16, 2024 | 4.61 | 0.06 | 1.32% | 4.55 | 4.63 | 4.50 |
| Apr 15, 2024 | 4.61 | -0.01 | -0.22% | 4.62 | 4.90 | 4.55 |
| Apr 12, 2024 | 4.56 | -0.19 | -4.00% | 4.75 | 4.78 | 4.51 |
| Apr 11, 2024 | 4.79 | -0.16 | -3.23% | 4.95 | 4.95 | 4.74 |
| Apr 10, 2024 | 4.96 | -0.08 | -1.59% | 5.04 | 5.04 | 4.92 |
| Apr 9, 2024 | 5.01 | -0.14 | -2.72% | 5.15 | 5.25 | 4.98 |
| Apr 8, 2024 | 5.18 | 0.12 | 2.37% | 5.06 | 5.23 | 4.98 |
| Apr 5, 2024 | 5.03 | 0.11 | 2.24% | 4.92 | 5.11 | 4.80 |
| Apr 4, 2024 | 4.91 | -0.08 | -1.60% | 4.99 | 5.13 | 4.91 |
| Apr 3, 2024 | 5.00 | 0.19 | 3.95% | 4.81 | 5.08 | 4.81 |
| Apr 2, 2024 | 5.00 | 0.00 | 0.00% | 5.00 | 5.13 | 4.93 |
| Apr 1, 2024 | 5.19 | 0.03 | 0.58% | 5.16 | 5.28 | 4.94 |
| Mar 28, 2024 | 5.17 | 0.01 | 0.19% | 5.16 | 5.30 | 5.11 |
| Mar 27, 2024 | 5.16 | 0.08 | 1.57% | 5.08 | 5.25 | 5.08 |
| Mar 26, 2024 | 5.13 | 0.03 | 0.59% | 5.10 | 5.20 | 4.99 |
| Mar 25, 2024 | 5.10 | -0.33 | -6.08% | 5.43 | 5.49 | 4.92 |
Bioventus Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, May 14, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 Bioventus Inc Earnings Release Q1 2024 Bioventus Inc Earnings ReleaseForecast -Previous - |
| Thursday, June 6, 2024 | ||
| Time (UTC) 14:00 | Country US
| Event Bioventus Inc Annual Shareholders Meeting Bioventus Inc Annual Shareholders MeetingForecast -Previous - |
| Tuesday, August 6, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q2 2024 Bioventus Inc Earnings Release Q2 2024 Bioventus Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 512.117 | 430.898 | 321.161 | 340.141 | 319.177 |
| Revenue | 512.117 | 430.898 | 321.161 | 340.141 | 319.177 |
| Cost of Revenue, Total | 181.037 | 128.192 | 87.642 | 90.935 | 84.168 |
| Gross Profit | 331.08 | 302.706 | 233.519 | 249.206 | 235.009 |
| Total Operating Expense | 763.165 | 420.999 | 295.801 | 311.933 | 293.673 |
| Selling/General/Admin. Expenses, Total | 332.606 | 254.253 | 187.469 | 198.206 | 191.672 |
| Research & Development | 25.941 | 19.039 | 11.202 | 11.055 | 8.095 |
| Depreciation / Amortization | 21.153 | 8.363 | 7.439 | 7.908 | 8.615 |
| Unusual Expense (Income) | 195.976 | 10.323 | 2.049 | 3.829 | 1.862 |
| Other Operating Expenses, Total | 6.452 | 0.829 | 0 | 0 | -0.739 |
| Operating Income | -251.048 | 9.899 | 25.36 | 28.208 | 25.504 |
| Interest Income (Expense), Net Non-Operating | -24.692 | 1.77 | -9.091 | -17.891 | -18.66 |
| Other, Net | 11.841 | -4.049 | -0.355 | -0.628 | -0.737 |
| Net Income Before Taxes | -263.899 | 7.62 | 15.914 | 9.689 | 6.107 |
| Net Income After Taxes | -213.391 | 9.586 | 14.722 | 8.113 | 4.443 |
| Minority Interest | 54.687 | 9.789 | 1.689 | 0.553 | 0 |
| Net Income Before Extra. Items | -158.704 | 19.375 | 16.411 | 8.666 | 4.443 |
| Total Extraordinary Items | 0 | 0 | -1.815 | -16.65 | |
| Net Income | -158.704 | 19.375 | 16.411 | 6.851 | -12.207 |
| Total Adjustments to Net Income | -12.028 | -7.51 | -5.781 | ||
| Income Available to Common Excl. Extra. Items | -158.704 | 19.375 | 4.383 | 1.156 | -1.338 |
| Income Available to Common Incl. Extra. Items | -158.704 | 19.375 | 4.383 | -0.659 | -17.988 |
| Diluted Net Income | -158.704 | 19.375 | 4.383 | -0.659 | -17.988 |
| Diluted Weighted Average Shares | 61.3891 | 45.4725 | 55.6253 | 55.6253 | 55.6253 |
| Diluted EPS Excluding Extraordinary Items | -2.58521 | 0.42608 | 0.0788 | 0.02078 | -0.02405 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -0.0549 | 1.03994 | 0.20655 | 0.16588 | 0.0261 |
| Jul 2023 | Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | |
|---|---|---|---|---|---|
| Total revenue | 137.069 | 119.059 | 125.834 | 128.662 | 140.331 |
| Revenue | 137.069 | 119.059 | 125.834 | 128.662 | 140.331 |
| Cost of Revenue, Total | 47.946 | 45.14 | 51.645 | 44.127 | 43.677 |
| Gross Profit | 89.123 | 73.919 | 74.189 | 84.535 | 96.654 |
| Total Operating Expense | 130.319 | 211.117 | 151.269 | 329.517 | 143.639 |
| Selling/General/Admin. Expenses, Total | 74.844 | 80.858 | 77.668 | 79.194 | 89.62 |
| Research & Development | 3.398 | 3.771 | 6.807 | 5.84 | 6.366 |
| Depreciation / Amortization | 2.294 | 2.129 | 7.761 | 7.442 | 2.696 |
| Operating Income | 6.75 | -92.058 | -25.435 | -200.855 | -3.308 |
| Interest Income (Expense), Net Non-Operating | -10.587 | -9.694 | -14.873 | -9.894 | -2.579 |
| Other, Net | -0.513 | 1.588 | -9.406 | 23.272 | -0.603 |
| Net Income Before Taxes | -4.35 | -100.164 | -49.714 | -187.477 | -6.49 |
| Net Income After Taxes | -4.731 | -100.018 | -44.873 | -145.698 | -7.734 |
| Minority Interest | 1.05 | 20.36 | 12.943 | 37.453 | 0.762 |
| Net Income Before Extra. Items | -3.681 | -79.658 | -31.93 | -108.245 | -6.972 |
| Net Income | -3.681 | -139.15 | -31.93 | -108.245 | -7.252 |
| Income Available to Common Excl. Extra. Items | -3.681 | -79.658 | -31.93 | -108.245 | -6.972 |
| Income Available to Common Incl. Extra. Items | -3.681 | -139.15 | -31.93 | -108.245 | -7.252 |
| Diluted Net Income | -3.681 | -139.15 | -31.93 | -108.245 | -7.252 |
| Diluted Weighted Average Shares | 62.5513 | 62.1247 | 61.9296 | 61.6743 | 61.4753 |
| Diluted EPS Excluding Extraordinary Items | -0.05885 | -1.28223 | -0.51559 | -1.75511 | -0.11341 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 0.04562 | -0.34997 | -0.29682 | 0.33166 | -0.02298 |
| Unusual Expense (Income) | 1.597 | 78.932 | 4.62 | 189.772 | 1.007 |
| Other Operating Expenses, Total | 0.24 | 0.287 | 2.768 | 3.142 | 0.273 |
| Total Extraordinary Items | 0 | -59.492 | -0.28 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 272.575 | 263.103 | 211.794 | 183.033 | 148.354 |
| Cash and Short Term Investments | 31.814 | 43.933 | 86.839 | 64.52 | 42.774 |
| Cash & Equivalents | 31.814 | 43.933 | 86.839 | 64.52 | 42.774 |
| Total Receivables, Net | 136.912 | 125.045 | 88.364 | 85.389 | 73.041 |
| Accounts Receivable - Trade, Net | 136.912 | 125.045 | 88.364 | 85.389 | 73.041 |
| Total Inventory | 85.408 | 61.688 | 29.12 | 27.326 | 27.396 |
| Prepaid Expenses | 18.418 | 27.157 | 7.471 | 5.798 | 4.713 |
| Other Current Assets, Total | 0.023 | 5.28 | 0.43 | ||
| Total Assets | 1372.65 | 1225.86 | 494.466 | 472.407 | 442.723 |
| Property/Plant/Equipment, Total - Net | 44.955 | 40.171 | 21.84 | 19.756 | 4.759 |
| Property/Plant/Equipment, Total - Gross | 75.827 | 52.818 | 42.161 | 37.998 | 23.515 |
| Accumulated Depreciation, Total | -30.872 | -23.1 | -20.321 | -18.242 | -18.756 |
| Goodwill, Net | 13.759 | 147.623 | 49.8 | 49.8 | 49.8 |
| Intangibles, Net | 1038.72 | 695.193 | 191.65 | 216.51 | 237.029 |
| Long Term Investments | 2.636 | 29.291 | 19.382 | 3.308 | 2.781 |
| Total Current Liabilities | 304.017 | 180.859 | 122.589 | 89.015 | 65.428 |
| Accounts Payable | 37.549 | 16.915 | 4.422 | 6.44 | 8.207 |
| Accrued Expenses | 113.11 | 137.713 | 98.767 | 67.633 | 48.952 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 33.056 | 18.038 | 15 | 10.041 | 5.25 |
| Other Current Liabilities, Total | 120.302 | 8.193 | 4.4 | 4.901 | 3.019 |
| Total Liabilities | 1056.07 | 766.938 | 352.225 | 329.425 | 297.456 |
| Total Long Term Debt | 385.01 | 339.644 | 173.378 | 187.978 | 189.578 |
| Long Term Debt | 385.01 | 339.644 | 173.378 | 187.965 | 189.578 |
| Deferred Income Tax | 154.001 | 133.518 | 3.362 | 3.874 | 3.955 |
| Minority Interest | 23.751 | 74.865 | 1.919 | 2.635 | 0 |
| Other Liabilities, Total | 189.289 | 38.052 | 50.977 | 45.923 | 38.495 |
| Total Equity | 316.581 | 458.924 | 142.241 | 142.982 | 145.267 |
| Redeemable Preferred Stock | 210.576 | 204.443 | 198.488 | ||
| Preferred Stock - Non Redeemable, Net | -42.576 | -36.443 | -30.488 | ||
| Common Stock | 0.078 | 0.075 | 113.373 | 113.373 | 113.373 |
| Retained Earnings (Accumulated Deficit) | -165.306 | -6.602 | -140.739 | -137.926 | -136.041 |
| Other Equity, Total | -0.11 | 0.179 | 1.607 | -0.465 | -0.065 |
| Total Liabilities & Shareholders’ Equity | 1372.65 | 1225.86 | 494.466 | 472.407 | 442.723 |
| Total Common Shares Outstanding | 77.8497 | 75.3352 | 55.6253 | 55.6253 | 55.6253 |
| Capital Lease Obligations | 0.013 | ||||
| Other Long Term Assets, Total | 0 | 50.481 | |||
| Additional Paid-In Capital | 481.919 | 465.272 |
| Sep 2023 | Jul 2023 | Apr 2023 | Dec 2022 | Oct 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 249.452 | 260.638 | 308.664 | 272.575 | 271.082 |
| Cash and Short Term Investments | 26.827 | 29.389 | 47.102 | 31.814 | 34.359 |
| Cash & Equivalents | 26.827 | 29.389 | 47.102 | 31.814 | 34.359 |
| Total Receivables, Net | 112.899 | 119.636 | 118.544 | 136.912 | 132.185 |
| Accounts Receivable - Trade, Net | 112.899 | 119.636 | 118.544 | 136.912 | 132.185 |
| Total Inventory | 97.563 | 96.276 | 87.953 | 85.408 | 76.952 |
| Prepaid Expenses | 12.163 | 15.337 | 17.192 | 18.418 | 27.563 |
| Other Current Assets, Total | 37.873 | 0.023 | 0.023 | ||
| Total Assets | 811.104 | 836.962 | 887.404 | 1372.65 | 1398.02 |
| Property/Plant/Equipment, Total - Net | 54.002 | 57.1 | 52.619 | 44.955 | 42.947 |
| Goodwill, Net | 7.462 | 7.462 | 7.462 | 13.759 | 15.359 |
| Intangibles, Net | 493.324 | 505.223 | 516.039 | 1038.72 | 1055.6 |
| Long Term Investments | 6.864 | 6.539 | 2.62 | 2.636 | 13.033 |
| Other Long Term Assets, Total | 0 | 0 | |||
| Total Current Liabilities | 160.843 | 179.104 | 196.063 | 304.017 | 288.373 |
| Accounts Payable | 17.637 | 41.364 | 32.828 | 37.549 | 19.075 |
| Accrued Expenses | 118.197 | 120.53 | 115.127 | 113.11 | 118.025 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 19.584 | 11.32 | 41.32 | 33.056 | 31.302 |
| Other Current Liabilities, Total | 5.425 | 5.89 | 6.788 | 120.302 | 119.971 |
| Total Liabilities | 633.575 | 653.767 | 698.893 | 1056.07 | 1054.62 |
| Total Long Term Debt | 375.033 | 374.568 | 404.265 | 385.01 | 393.102 |
| Long Term Debt | 375.033 | 374.568 | 404.265 | 385.01 | 393.102 |
| Deferred Income Tax | 0 | 0 | 0.351 | 154.001 | 159.3 |
| Minority Interest | 48.927 | 50.146 | 51.851 | 23.751 | 35.749 |
| Other Liabilities, Total | 48.772 | 49.949 | 46.363 | 189.289 | 178.101 |
| Total Equity | 177.529 | 183.195 | 188.511 | 316.581 | 343.397 |
| Common Stock | 0.079 | 0.079 | 0.079 | 0.078 | 0.08 |
| Additional Paid-In Capital | 492.493 | 490.598 | 492.475 | 481.919 | 478.033 |
| Retained Earnings (Accumulated Deficit) | -315.44 | -308.137 | -304.456 | -165.306 | -133.376 |
| Other Equity, Total | 0.397 | 0.655 | 0.413 | -0.11 | -1.34 |
| Total Liabilities & Shareholders’ Equity | 811.104 | 836.962 | 887.404 | 1372.65 | 1398.02 |
| Total Common Shares Outstanding | 78.7512 | 78.5912 | 78.2946 | 77.8497 | 77.5646 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -213.391 | 9.586 | 14.722 | 6.298 | -12.207 |
| Cash From Operating Activities | -13.537 | 22.991 | 71.799 | 40.713 | 45.187 |
| Cash From Operating Activities | 66.803 | 34.875 | 28.643 | 30.316 | 29.238 |
| Deferred Taxes | -52.792 | -9.756 | -0.511 | -0.348 | -0.079 |
| Non-Cash Items | 200.375 | 1.563 | 13.637 | 18.019 | 25.383 |
| Cash Taxes Paid | 1.518 | 7.456 | 1.541 | 1.577 | 1.944 |
| Cash Interest Paid | 18.043 | 5.837 | 7.486 | 15.45 | 17.273 |
| Changes in Working Capital | -14.532 | -13.277 | 15.308 | -13.572 | 2.852 |
| Cash From Investing Activities | -116.436 | -283.76 | -20.5 | -7.912 | -6.101 |
| Capital Expenditures | -10.042 | -7.37 | -4.093 | -2.342 | -2.561 |
| Other Investing Cash Flow Items, Total | -106.394 | -276.39 | -16.407 | -5.57 | -3.54 |
| Cash From Financing Activities | 62.076 | 273.371 | -29.569 | -10.951 | -13.256 |
| Financing Cash Flow Items | -3.367 | -2.242 | -19.569 | -9.504 | -7.846 |
| Issuance (Retirement) of Debt, Net | 59.621 | 166.203 | -10 | -1.447 | -5.41 |
| Foreign Exchange Effects | 0.521 | -0.228 | 0.589 | -0.104 | -0.16 |
| Net Change in Cash | -67.376 | 12.374 | 22.319 | 21.746 | 25.67 |
| Issuance (Retirement) of Stock, Net | 5.822 | 109.41 |
| Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | Apr 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -174.447 | -213.391 | -168.518 | -22.82 | -14.806 |
| Cash From Operating Activities | 2.49 | -13.537 | -18.781 | -18.08 | -21.019 |
| Cash From Operating Activities | 16.473 | 66.803 | 43.643 | 24.863 | 12.479 |
| Deferred Taxes | -2.664 | -52.792 | -47.154 | -27.698 | -17.018 |
| Non-Cash Items | 155.058 | 200.375 | 183.873 | 9.784 | 2.633 |
| Changes in Working Capital | 8.07 | -14.532 | -30.625 | -2.209 | -4.307 |
| Cash From Investing Activities | -15.066 | -116.436 | -113.033 | -56.699 | -4.674 |
| Capital Expenditures | -3.56 | -10.042 | -6.639 | -4.99 | -2.96 |
| Other Investing Cash Flow Items, Total | -11.506 | -106.394 | -106.394 | -51.709 | -1.714 |
| Cash From Financing Activities | 27.38 | 62.076 | 67.514 | 16.86 | 9.205 |
| Financing Cash Flow Items | -1.704 | -3.367 | -3.356 | -3.378 | -3.366 |
| Issuance (Retirement) of Stock, Net | 0.084 | 5.822 | 4.739 | 4.257 | 2.08 |
| Issuance (Retirement) of Debt, Net | 29 | 59.621 | 66.131 | 15.981 | 10.491 |
| Foreign Exchange Effects | 0.461 | 0.521 | -0.531 | -0.293 | -0.071 |
| Net Change in Cash | 15.265 | -67.376 | -64.831 | -58.212 | -16.559 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Bioventus Inc. Company profile
About Bioventus Inc
Bioventus Inc is a global medical device company. The Company is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Bioventus Inc revenues increased 34% to $430.9M. Net income applicable to common stockholders increased from $4.4M to $19.4M. Revenues reflect U.S. segment increase of 32% to $387.6M, International segment increase of 58% to $43.3M. Net income benefited from Stock-based Compensation in SGA decrease from $10.1M (expense) to $4.5M (income), Foreign Exchange Gain/Loss increase of 13% to $132K (income).
| Industry: | Medical Equipment |
4721 Emperor Boulevard, Suite 100
DURHAM
NORTH CAROLINA 27703
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com